Tumor Biology

, Volume 34, Issue 1, pp 223–230 | Cite as

Significant association between CYP1A1 T3801C polymorphism and cervical neoplasia risk: a systematic review and meta-analysis

  • Liangbin Xia
  • Jing Gao
  • Yan Liu
  • Ke Wu
Research Article


Recently, many studies have been published to evaluate the correlation between the cytochrome P450 1A1 (CYP1A1) T3801C polymorphism and cervical neoplasia risk. However, the results remain inconclusive. To clarify this possible association, we conducted a systematic review and meta-analysis of published studies. Data were collected from the following electronic databases: PubMed, Embase, Ovid, ISI Web of Knowledge, Google Scholar, and Chinese Biomedical Database databases. The pooled odds ratio (OR) and its 95 % confidence interval (95 % CI) were used to assess the strength of this association. The pooled ORs were performed for the allele model (C vs. T), the homozygote model (CC vs. TT), the dominant model (CC/CT vs. TT), and the recessive model (CC vs. TT/CT), respectively. Finally, a total of 12 independent studies including a total of 3,724 subjects (1,912 cases/1,812 controls) were eligible for meta-analysis. Overall, there was a significant association between the CYP1A1 T3801C polymorphism and cervical neoplasia susceptibility (C vs. T, OR 1.32, 95 % CI 1.04–1.68, P = 0.02; CC vs. TT, OR 1.99, 95 % CI 1.19–3.35, P = 0.01; CC/CT vs. TT, OR 1.36, 95 % CI 1.02–1.81, P = 0.02; CC vs. TT/CT, OR 1.57, 95 % CI 1.23–2.02, P < 0.01). Meta-analysis of the ten studies on cervical cancer suggested a significant association between the CYP1A1 T3801C polymorphism and cervical cancer risk (C vs. T, OR 1.38, 95 % CI 1.05–1.82, P = 0.02; CC vs. TT, OR 2.06, 95 % CI 1.15–3.70, P = 0.02; CC/CT vs. TT, OR 1.45, 95 % CI 1.03–2.02, P = 0.03; CC vs. TT/CT, OR 1.56, 95 % CI 1.20–2.03, P < 0.01). In the stratified analysis by ethnicity, significant associations were also detected in some genetic models. This meta-analysis demonstrates a significant association between the CYP1A1 T3801C polymorphism and cervical neoplasia susceptibility.


Cervical neoplasia CYP1A1 Meta-analysis Polymorphism 



We thank all the people who give technical support and useful discussion of the paper.

Conflicts of interest



  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRefGoogle Scholar
  2. 2.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.PubMedCrossRefGoogle Scholar
  3. 3.
    Sahasrabuddhe VV, Parham GP, Mwanahamuntu MH, Vermund SH. Cervical cancer prevention in low- and middle-income countries: feasible, affordable, essential. Cancer Prev Res (Phila). 2012;5:11–7.CrossRefGoogle Scholar
  4. 4.
    Gouy S, Morice P, Narducci F, Uzan C, Gilmore J, Kolesnikov-Gauthier H, et al. Nodal-staging surgery for locally advanced cervical cancer in the era of pet. Lancet Oncol. 2012;13:e212–20.PubMedCrossRefGoogle Scholar
  5. 5.
    Kocken M, Uijterwaal MH, de Vries AL, Berkhof J, Ket JC, Helmerhorst TJ, et al. High-risk human papillomavirus testing versus cytology in predicting post-treatment disease in women treated for high-grade cervical disease: a systematic review and meta-analysis. Gynecol Oncol. 2012;125:500–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Anderson LA. Prophylactic human papillomavirus vaccines: past, present and future. Pathology. 2012;44:1–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Liu D, Zhou P, Zhang L, Wu G, Zheng Y, He F. Differential expression of Oct4 in HPV-positive and HPV-negative cervical cancer cells is not regulated by DNA methyltransferase 3A. Tumour Biol. 2011;32:941–50.PubMedCrossRefGoogle Scholar
  8. 8.
    Vasilevska M, Ross SA, Gesink D, Fisman DN. Relative risk of cervical cancer in indigenous women in Australia, Canada, New Zealand, and the United States: a systematic review and meta-analysis. J Public Health Policy. 2012;33:148–64.PubMedCrossRefGoogle Scholar
  9. 9.
    Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62:147–72.PubMedCrossRefGoogle Scholar
  10. 10.
    Moore EE, Wark JD, Hopper JL, Erbas B, Garland SM. The roles of genetic and environmental factors on risk of cervical cancer: a review of classical twin studies. Twin Res Hum Genet. 2012;15:79–86.PubMedCrossRefGoogle Scholar
  11. 11.
    Barbisan G, Perez LO, Contreras A, Golijow CD. TNF-alpha and IL-10 promoter polymorphisms, HPV infection, and cervical cancer risk. Tumour Biol. 2012.Google Scholar
  12. 12.
    Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011;12:663–72.PubMedCrossRefGoogle Scholar
  13. 13.
    Tsuchiya Y, Nakajima M, Yokoi T. Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett. 2005;227:115–24.PubMedCrossRefGoogle Scholar
  14. 14.
    Sangar MC, Bansal S, Avadhani NG. Bimodal targeting of microsomal cytochrome P450s to mitochondria: implications in drug metabolism and toxicity. Expert Opin Drug Metab Toxicol. 2010;6:1231–51.PubMedCrossRefGoogle Scholar
  15. 15.
    Androutsopoulos VP, Tsatsakis AM, Spandidos DA. Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention. BMC Cancer. 2009;9:187.PubMedCrossRefGoogle Scholar
  16. 16.
    Nebert DW, Dalton TP. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer. 2006;6:947–60.PubMedCrossRefGoogle Scholar
  17. 17.
    Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009;41:89–295.PubMedCrossRefGoogle Scholar
  18. 18.
    Mrozikiewicz PM, Grzeskowiak E, Seremak-Mrozikiewicz A, Bogacz A, Barlik M, Semczuk A, et al. Importance of CYP1A1 polymorphism and its transcriptional regulation in ovarian and endometrial cancer. Ginekol Pol. 2011;82:925–32.PubMedGoogle Scholar
  19. 19.
    Dong LM, Potter JD, White E, Ulrich CM, Cardon LR, Peters U. Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA. 2008;299:2423–36.PubMedCrossRefGoogle Scholar
  20. 20.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  21. 21.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRefGoogle Scholar
  22. 22.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRefGoogle Scholar
  23. 23.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRefGoogle Scholar
  24. 24.
    Ding FY, Ma GF, Song XH, Shi WH, Lan JY, Yu HY. Relationship between CYP1A1 gene polymorphism and genetic susceptibility of cervical carcinoma. Jiangsu Med J. 2011;37:2562–4.Google Scholar
  25. 25.
    Shi YR, Geng J, Cheng LQ, Wang H, Zhang Y. Association of cytochrome P450 1A1 gene polymorphisms with cervical cancer. Fudan Univ J Med Sci. 2011;38:428–31.Google Scholar
  26. 26.
    Zhang SH, Kong AR. Polymorphisms of CYP1A1 gene and HPV infection of cervical squamous carcinoma. Master’s thesis of Taishan Medical University 2009;2009Google Scholar
  27. 27.
    Taskiran C, Aktas D, Yigit-Celik N, Alikasifoglu M, Yuce K, Tuncbilek E, et al. CYP1A1 gene polymorphism as a risk factor for cervical intraepithelial neoplasia and invasive cervical cancer. Gynecol Oncol. 2006;101:503–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Agorastos T, Papadopoulos N, Lambropoulos AF, Chrisafi S, Mikos T, Goulis DG, et al. Glutathione-S-transferase M1 and T1 and cytochrome P1A1 genetic polymorphisms and susceptibility to cervical intraepithelial neoplasia in Greek women. Eur J Cancer Prev. 2007;16:498–504.PubMedCrossRefGoogle Scholar
  29. 29.
    Goodman MT, McDuffie K, Hernandez B, Bertram CC, Wilkens LR, Guo C, et al. CYP1A1, GSTM1, and GSTT1 polymorphisms and the risk of cervical squamous intraepithelial lesions in a multiethnic population. Gynecol Oncol. 2001;81:263–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Gutman G, Morad T, Peleg B, Peretz C, Bar-Am A, Safra T, et al. CYP1A1 and CYP2D6 gene polymorphisms in Israeli Jewish women with cervical cancer. Int J Gynecol Cancer. 2009;19:1300–2.PubMedCrossRefGoogle Scholar
  31. 31.
    Joseph T, Chacko P, Wesley R, Jayaprakash PG, James FV, Pillai MR. Germline genetic polymorphisms of CYP1A1, GSTM1 and GSTT1 genes in indian cervical cancer: associations with tumor progression, age and human papillomavirus infection. Gynecol Oncol. 2006;101:411–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Juarez-Cedillo T, Vallejo M, Fragoso JM, Hernandez-Hernandez DM, Rodriguez-Perez JM, Sanchez-Garcia S, et al. The risk of developing cervical cancer in Mexican women is associated to CYP1A1 MspI polymorphism. Eur J Cancer. 2007;43:1590–5.PubMedCrossRefGoogle Scholar
  33. 33.
    Kim JW, Lee CG, Park YG, Kim KS, Kim IK, Sohn YW, et al. Combined analysis of germline polymorphisms of p53, GSTM1, GSTT1, CYP1A1, and CYP2E1: relation to the incidence rate of cervical carcinoma. Cancer. 2000;88:2082–91.PubMedCrossRefGoogle Scholar
  34. 34.
    Nishino K, Sekine M, Kodama S, Sudo N, Aoki Y, Seki N, et al. Cigarette smoking and glutathione S-transferase M1 polymorphism associated with risk for uterine cervical cancer. J Obstet Gynaecol Res. 2008;34:994–1001.PubMedGoogle Scholar
  35. 35.
    Sugawara T, Nomura E, Sagawa T, Sakuragi N, Fujimoto S. CYP1A1 polymorphism and risk of gynecological malignancy in Japan. Int J Gynecol Cancer. 2003;13:785–90.PubMedCrossRefGoogle Scholar
  36. 36.
    von Keyserling H, Bergmann T, Schuetz M, Schiller U, Stanke J, Hoffmann C, et al. Analysis of 4 single-nucleotide polymorphisms in relation to cervical dysplasia and cancer development using a high-throughput ligation-detection reaction procedure. Int J Gynecol Cancer. 2011;21:1664–71.CrossRefGoogle Scholar
  37. 37.
    Seliskar M, Rozman D. Mammalian cytochromes P450—importance of tissue specificity. Biochim Biophys Acta. 2007;1770:458–66.PubMedCrossRefGoogle Scholar
  38. 38.
    Masson LF, Sharp L, Cotton SC, Little J. Cytochrome P-450 1A1 gene polymorphisms and risk of breast cancer: a huge review. Am J Epidemiol. 2005;161:901–15.PubMedCrossRefGoogle Scholar
  39. 39.
    Lourenco GJ, Silva EF, Rinck-Junior JA, Chone CT, Lima CS. CYP1A1, GSTM1 and GSTT1 polymorphisms, tobacco and alcohol status and risk of head and neck squamous cell carcinoma. Tumour Biol. 2011;32:1209–15.PubMedCrossRefGoogle Scholar
  40. 40.
    Luo YP, Chen HC, Khan MA, Chen FZ, Wan XX, Tan B, et al. Genetic polymorphisms of metabolic enzymes-CYP1A1, CYP2D6, GSTM1, and GSTT1, and gastric carcinoma susceptibility. Tumour Biol. 2011;32:215–22.PubMedCrossRefGoogle Scholar
  41. 41.
    Guo R, Guo X. Quantitative assessment of the associations between CYP1A1 polymorphisms and gastric cancer risk. Tumour Biol. 2012;33:1125–32.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2012

Authors and Affiliations

  1. 1.Department of Obstetrics and GynecologyRenmin Hospital of Wuhan UniversityHubeiChina
  2. 2.Department of General SurgeryZhongnan Hospital of Wuhan UniversityWuhanChina
  3. 3.Center for Animal Experiment, ABSL-3 Laboratory, Center for Medical ResearchWuhan UniversityHubeiChina

Personalised recommendations